Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.33 |
| ▸ | AGER | Q15109 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599786 | 0.89 | CNR1 (0.47) | CNR1MGAT2FFAR1FFAR4 | |
| SCHEMBL4243035 | 0.89 | CNR1 (0.48) | CNR1PTGDR2PPARAFFAR1FFAR4 | |
| SCHEMBL4247679 | 0.85 | CNR1 (0.57) | CNR1PTGDR2SLC2A1 | |
| SCHEMBL4599782 | 0.84 | CNR1 (0.42) | CNR1PTGDR2SMN1; SMN2MGAT2FFAR1 | |
| SCHEMBL4600547 | 0.73 | CNR1 (0.69) | CNR1SLC2A1 | |
| SCHEMBL4681021 | 0.73 | CNR1 (0.57) | CNR1PTGDR2SMN1; SMN2SLC2A1MRGPRX4 | |
| SCHEMBL4248289 | 0.71 | CNR1 (0.61) | CNR1FFAR1FFAR4 | |
| SCHEMBL4247678 | 0.71 | CNR1 (0.57) | CNR1PTGDR2MAPTSMN1; SMN2SLC2A1 | |
| SCHEMBL4600541 | 0.71 | CNR1 (0.65) | CNR1PTGDR2SMN1; SMN2 | |
| SCHEMBL4680862 | 0.70 | CNR1 (0.59) | CNR1PTGDR2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | claimed |
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| EP-1910304-A2 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010222-A2 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | NLN, BDNF, GAP43 | CNR1 173/4885PTGDR2 379/4885MAPT 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.